674 related articles for article (PubMed ID: 25333856)
1. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
2. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases.
Todenhöfer T; Hennenlotter J; Schmiedel BJ; Hohneder A; Grimm S; Kühs U; Salih HR; Bühring HJ; Fehm T; Gakis G; Blumenstock G; Aufderklamm S; Schilling D; Stenzl A; Schwentner C
Prostate; 2013 Jan; 73(2):162-8. PubMed ID: 22715006
[TBL] [Abstract][Full Text] [Related]
4. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
5. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
6. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.
Christoph F; König F; Lebentrau S; Jandrig B; Krause H; Strenziok R; Schostak M
World J Urol; 2018 Feb; 36(2):187-192. PubMed ID: 29204705
[TBL] [Abstract][Full Text] [Related]
7. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
8. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.
Galeone A; Brunetti G; Rotunno C; Oranger A; Colucci S; de Luca Tupputi Schinosa L; Zallone A; Grano M; Paparella D
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e141-7. PubMed ID: 23671202
[TBL] [Abstract][Full Text] [Related]
9. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
[TBL] [Abstract][Full Text] [Related]
10. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
[TBL] [Abstract][Full Text] [Related]
11. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
[TBL] [Abstract][Full Text] [Related]
12. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
13. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
14. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Kawamura K; Imamoto T; Takanami M; Ichikawa T
Int J Clin Oncol; 2011 Aug; 16(4):366-72. PubMed ID: 21327451
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
[TBL] [Abstract][Full Text] [Related]
16. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
18. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D; Maalouf NM; Sakhaee K
J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
[TBL] [Abstract][Full Text] [Related]
19. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
[TBL] [Abstract][Full Text] [Related]
20. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
